Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 407

The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.

Mechanisms of aromatase inhibitor resistance

Ma, Cynthia X., Reinert, Tomás, Chmielewska, Izabela, Ellis, Matthew J.·2015·Nature Reviews Cancer

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc3920

Cites

174 of 174 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 174 references

Research works printed but not linked: 15

  1. Ellis, M. J. et al. Z1031B neoadjuvant aromatase inhibitor trial: a phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%. Cancer Res. 72, PD07-01 (2012). · doi:10.1158/0008-5472.sabcs12-pd07-01
  2. Ellis, M. J. et al. Tumor Ki67 proliferation index within 4 weeks of initiating neoadjuvant endocrine therapy for early identification of non-responders. Cancer Res. 69, 78 (2009). · doi:10.1158/0008-5472.sabcs-09-78
  3. Goncalves, R. et al. A Ki67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. J. Pharmacogenomics Pharmacoproteomics 5, 5 (2014).
  4. Fan, P. et al. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur. J. Cancer 50, 457–468 (2014). · doi:10.1016/j.ejca.2013.10.001
  5. Vincent-Salomon, A., Raynal, V., Lucchesi, C., Gruel, N. & Delattre, O. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 809 (2008). · doi:10.1038/ng0708-809a
  6. Horlings, H. M. et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 807–808 (2008). · doi:10.1038/ng0708-807
  7. Holst, F. et al. On the evidence for ESR1 amplification in breast cancer. Nature Rev. Cancer 12, 149 (2012). · doi:10.1038/nrc3093-c3
  8. Moelans, C. B. et al. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Anal. Cell. Pathol. (Amst.) 33, 13–18 (2010). · doi:10.1155/2010/619180
  9. Kaufman, P. A. et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res. 70, S1–S4 (2010). · doi:10.1158/0008-5472.can-09-4246
  10. Hortobagyi, G. N. et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J. Clin. Oncol. 31, LBA509 (2013). · doi:10.1200/jco.2013.31.18_suppl.lba509
  11. Giacinti, L. et al. Scriptaid effects on breast cancer cell lines. J. Cell. Physiol. 227, 3426–3433 (2012). · doi:10.1002/jcp.24043
  12. Marks, P. A. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 3, 534–535 (2004). · doi:10.4161/cc.3.5.824
  13. Bianchini, G. et al. A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer. J. Clin. Oncol. 30, 545 (2012). · doi:10.1200/jco.2012.30.4_suppl.545
  14. Piccart, M. et al. Assessment of genetic alterations in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer from the BOLERO-2 trial by next-generation sequencing. Ann. Oncol. 24 (Suppl. 3), 25–26 (2013). · doi:10.1093/annonc/mdt083.3
  15. Adelson, K. B., Raptis, G., Sparano, J. & Germain, D. Randomized phase II study of fulvestrant versus fulvestrant plus bortezomib in postmenopausal women with estrogen receptor (ER) positive, aromatase-inhibitor (AI) resistant metastatic breast cancer (MBC): New York Cancer Consortium trial P8457. Cancer Res. 71, OT3-01-01 (2014). · doi:10.1158/0008-5472.sabcs11-ot3-01-01

Cited by

See all 407

Metadata

Authors
Ma, C. X., Reinert, T., Chmielewska, I., & Ellis, M. J.
Venue
Nature Reviews Cancer
Published
2015-04-24
Volume
15
Issue
5
Pages
261-275
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W1992533338
Cited by
407
References
174
FWCI
6.03
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of aromatase inhibitor resistance. https://app.cochat.ai/papers/10.1038/nrc3920
The paper
Ma, C. X., Reinert, T., Chmielewska, I., & Ellis, M. J. (2015). Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer. https://doi.org/10.1038/nrc3920

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.